Stemline Therapeutics (STML) PT Lowered to $11 at Wedbush
Wedbush analyst David Nierengarten lowered the price target on Stemline Therapeutics (NASDAQ: STML) to $11.00 (from $14.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Australian Pharma (API:AU) PT Raised to AUD1.55 at Credit Suisse
- SCG Packaging PCL (SCGP:TB) PT Raised to THB69 at Macquarie
- China Education Group Holdings Ltd. (839:HK) PT Lowered to HK$18.50 at CLSA
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!